登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●减持计划实施前股东持股的基本情况 本次减持计划实施前，大参林（维权）医药集团股份有限公司（以下简称"公司"）控股股东及其一致行 动人合计持有公司股份729,368,982股，占公司总股本的64.04%，其中，柯金龙持有公司股份 229,631,849股，占公司总股本比例为20.16%。 ●减持计划的实施结果情况 2025年6月5日，公司在上海证券交易所披露了《持股5%以上股东减持股份计划公告》（公告编号： 2025-036），为调整资产和融资结构，偿还个人债务，降低股票质押率，股东柯金龙拟通过大宗交易减 持其持有的公司股份不超过22,776,957股，即不超过公司总股本的2%。 截至2025年9月9日，柯金龙已通过大宗交易方式减持22,700,000股，占公司总股本的1.99%。截至本公 告披露日，上述减持计划已实施完毕。 本次减持计划完成后，控股股东及一致行动人合计持有公司股份由729,368,982 ...

Summary of Key Points Core Viewpoint - The announcement details the completion of a share reduction plan by a major shareholder of Dacianlin Pharmaceutical Group Co., Ltd., which has resulted in a decrease in the shareholding percentage of the controlling shareholder and its concerted parties. Group 1: Shareholding Before Reduction - Before the implementation of the reduction plan, the controlling shareholder and its concerted parties held a total of 729,368,982 shares, accounting for 64.04% of the total share capital of the company, with Ke Jinlong holding 229,631,849 shares, representing 20.16% of the total share capital [2]. Group 2: Implementation of Reduction Plan - On June 5, 2025, the company disclosed a share reduction plan, where Ke Jinlong intended to reduce his holdings by up to 22,776,957 shares, or 2% of the total share capital, through block trading to adjust asset and financing structures, repay personal debts, and lower stock pledge rates [3]. - As of September 9, 2025, Ke Jinlong successfully reduced his holdings by 22,700,000 shares, which is 1.99% of the total share capital. Following this reduction, the total shares held by the controlling shareholder and concerted parties decreased to 706,668,982 shares, resulting in a new holding percentage of 62.05% [3][4]. Group 3: Post-Reduction Shareholding and Compliance - The completion of the reduction plan does not trigger a mandatory tender offer and does not lead to any changes in the controlling shareholder or actual controller of the company. The company will continue to ensure compliance with relevant disclosure obligations by the information disclosure obligors [5].

证券代码：603233 证券简称：大参林 公告编号：2025-056 大参林医药集团股份有限公司 关于持股 5%以上股东权益变动触及 1%刻度暨减持计划实施 完毕的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 减持计划实施前股东持股的基本情况 本次减持计划实施前，大参林医药集团股份有限公司（以下简称"公 司"）控股股东及其一致行动人合计持有公司股份 729,368,982 股，占公司 总股本的 64.04%，其中，柯金龙持有公司股份 229,631,849 股，占公司总 股本比例为 20.16%。 减持计划的实施结果情况 2025 年 6 月 5 日，公司在上海证券交易所披露了《持股 5%以上股东减 持股份计划公告》（公告编号：2025-036），为调整资产和融资结构，偿还 个人债务，降低股票质押率，股东柯金龙拟通过大宗交易减持其持有的公 司股份不超过 22,776,957 股，即不超过公司总股本的 2%。 截至 2025 年 9 月 9 日，柯金龙已通过大宗交易方式减持 22,700,000 ...

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.29% on September 10, with Dazhenglin leading the drop [1] - The Shanghai Composite Index closed at 3812.22, up 0.13%, while the Shenzhen Component Index closed at 12557.68, up 0.38% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Seer Medical (603716) rising by 3.99% to a closing price of 28.70, and Dazhenglin (603233) falling by 2.37% to 17.30 [1][2] - Other notable gainers included Guofa Co. (600538) with a 1.65% increase and Dazhangzhang (002462) with a 1.22% increase [1] Trading Volume and Value - Seer Medical had a trading volume of 250,500 shares and a transaction value of 719 million yuan, while Dazhenglin had a trading volume of 77,200 shares and a transaction value of 134 million yuan [1][2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 11.87 million yuan from institutional investors and 50.86 million yuan from speculative funds, while retail investors contributed a net inflow of 62.74 million yuan [2] - Specific stocks like Seer Medical and Jiuzhoutong (600998) had significant net inflows from institutional investors, while others like Yifeng Pharmacy (603939) experienced net outflows from both institutional and speculative funds [3]

Core Insights - The traditional pharmacy industry in China is facing significant transformation challenges due to changing economic conditions, industry policies, and consumer habits, necessitating a differentiated approach to development [1][3][9] Group 1: Industry Transformation - The pharmacy industry must break through homogenized development and pursue differentiated transformation to address various pain points, including slowing growth, high store counts, and the need to attract younger consumers [1][3] - The Chinese pharmacy market is likely to split into two categories: specialized pharmacies focusing on professional medication needs and diversified pharmacies catering to daily health requirements [1][3] Group 2: Specialized Pharmacy Development - Specialized pharmacies are expected to respond to policy directions by actively engaging in prescription outflow, with a focus on enhancing professional capabilities [4][5] - The dual-channel policy is anticipated to accelerate the outflow of prescriptions to retail pharmacies, improving drug accessibility [5][6] Group 3: Diversified Pharmacy Development - Diversified pharmacies are encouraged to adopt a health care philosophy, utilizing digitalization to tailor product offerings and store layouts to specific consumer demographics [7][8] - The transformation costs for diversified pharmacies are relatively low, allowing for a shift in focus from traditional drug sales to a variety of health-related products [7] Group 4: Market Outlook - The industry is expected to experience a mild recovery by 2025, driven by ongoing trends in prescription outflow and increased market concentration [9] - Key players in the pharmacy sector, such as Yifeng Pharmacy, Yixin Hall, and Dazhenlin, are highlighted for their strong operational resilience and diverse transformation strategies [9]

证券时报·数据宝统计显示，大参林今日收盘价为17.72元，上涨0.11%，日换手率为0.69%，成交额为 1.38亿元，全天主力资金净流出634.89万元，近5日该股累计上涨2.78%，近5日资金合计净流出1765.75 万元。 大参林9月9日大宗交易平台共发生8笔成交，合计成交量2270.00万股，成交金额3.74亿元。成交价格均 为16.48元，相对今日收盘价折价7.00%。从参与大宗交易营业部来看，机构专用席位共出现在8笔成交 的买方或卖方营业部中，合计成交金额为3.74亿元，净买入3.74亿元。 两融数据显示，该股最新融资余额为2.25亿元，近5日减少1025.80万元，降幅为4.36%。 机构评级来看，近5日共有4家机构给予该股评级，预计目标价最高的是东方证券，9月8日东方证券发布 的研报预计公司目标价为20.16元。（数据宝） 9月9日大参林大宗交易一览 | 成交量 | 成交金额 | 成交价格 | 相对当日收盘折 | 买方营 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | 溢价（%） | 业部 | | | ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 9月9日，大参林（维权）收涨0.11%，收盘价为17.72元，发生8笔大宗交易，合计成交量2270万股，成 交金额3.74亿元。 第1笔成交价格为16.48元，成交600.00万股，成交金额9,888.00万元，溢价率为-7.00%，买方营业部为机 构专用，卖方营业部为中信证券股份有限公司深圳深南中路中信大厦证券营业部。 第2笔成交价格为16.48元，成交454.00万股，成交金额7,481.92万元，溢价率为-7.00%，买方营业部为机 构专用，卖方营业部为中信证券股份有限公司深圳深南中路中信大厦证券营业部。 第5笔成交价格为16.48元，成交300.00万股，成交金额4,944.00万元，溢价率为-7.00%，买方营业部为机 构专用，卖方营业部为中信证券股份有限公司深圳深南中路中信大厦证券营业部。 第6笔成交价格为16.48元，成交243.00万股，成交金额4,004.64万元，溢价率为-7.00%，买方营业部为机 构专用，卖方营业部为中信证券股份有限公司深圳深南中路中信大厦证券营业部。 第7笔成交价格为16.48元，成交22.00 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) with a target price of 20.16 CNY [1][6] Core Views - The company has shown steady revenue growth and a turning point in profits, with a focus on improving efficiency and performance [5][10] - The retail business experienced a slight decline, while the franchise and distribution business performed well, indicating a shift in revenue sources [10] - The company is actively optimizing its store network and expanding its new retail business, achieving significant growth in online sales [10] Financial Performance Summary - Revenue for 2025 is projected to be 29.649 billion CNY, with a year-on-year growth of 11.9% [8] - The net profit attributable to the parent company is forecasted to be 1.096 billion CNY in 2025, reflecting a year-on-year increase of 19.8% [8] - The company achieved a gross margin of 35.0% and a net margin of 3.7% in 2025 [8] - The earnings per share (EPS) is expected to be 0.96 CNY in 2025, with a projected increase to 1.37 CNY by 2027 [8] Market Performance - The company's stock has shown a 37.33% increase over the past 12 months, outperforming the market index [2]

Group 1: New Energy Sector - The new energy sector has seen a significant rise, driven by capital flow towards relatively undervalued stocks, as previous high valuations in computing power stocks led to a shift in investor sentiment [2] - There is a slight improvement in the fundamentals of the new energy sector, but market consensus on sustaining this trend remains divided, with factors such as AIDC, solid-state batteries, and overall capital expenditure in lithium batteries contributing to the outlook [2] - It is advised to consider reducing positions in overvalued stocks while continuing to monitor those with reasonable valuations as the sector rotates [2] Group 2: Macro Economic Insights - The August non-farm payroll data showed a weakening trend, which was anticipated based on prior unemployment claims and ADP data, yet it remains positive, alleviating immediate recession fears [3] - The current unemployment rate is still above the threshold of 4.5%, suggesting that the Federal Reserve may have room to lower interest rates, with a 25 basis point cut in September appearing likely [3] Group 3: Real Estate Market - In August, the total area of residential land sold in 30 core cities decreased by 42.1% year-on-year, with an average floor price of 8,145 yuan per square meter, reflecting a 7.0% increase year-on-year [14] - The top 10 real estate companies saw a 12% month-on-month increase in sales, but a 3% year-on-year decline, indicating a divergence in performance among leading firms [15] - Recommendations include companies like China Merchants Shekou, China Jinmao, and others that are expected to benefit from urban renewal and structural optimization [15] Group 4: Pharmaceutical Sector - The investment strategy for innovative drugs post-licensing emphasizes that achieving licensing is not the end of value realization but a pivotal point for further development [16] - The actual sales peak of innovative drugs often diverges significantly from initial expectations, with market sentiment playing a crucial role in valuation [16] Group 5: Company-Specific Insights - Poly Developments maintained its leading position in sales with a signed amount of 181.2 billion yuan from January to August 2025, focusing on core cities [17] - GCL-Poly Energy's cash cost for granular silicon continues to decline, with a market share increase to 24.3% in the first half of 2025, indicating strong competitive positioning [19] - Jin Kai New Energy reported a revenue of 1.922 billion yuan in the first half of 2025, reflecting a 2.07% year-on-year increase, with a focus on expanding its project portfolio [20]

Macro Strategy - The report highlights the need to monitor domestic economic policy changes due to the upcoming Fourth Plenary Session and the focus on countering "involution" [1] Fixed Income - The report discusses why domestic commercial banks are unlikely to reduce their balance sheets, citing factors such as the need to support the economy during a slowdown, the current accommodative monetary policy, and the role of state-owned capital in maintaining financial services to the real economy [2][22] - It emphasizes that the probability of a sector-wide balance sheet reduction is low, despite some smaller banks potentially facing this situation [22] Industry Analysis - The environmental industry report indicates that the waste incineration sector saw a revenue increase of 1% year-on-year in H1 2025, with net profit rising by 8% and an improvement in cash flow [4][6] - The report notes that operational efficiency improvements and reduced financial costs are driving performance growth, with a significant increase in return on equity (ROE) for pure waste operation companies [4][6] - It highlights the importance of enhancing operational efficiency and expanding both B-end and C-end markets to boost profitability and cash flow [6] Food and Beverage Industry - The beer industry report suggests that the sector is expected to benefit from a recovery in consumption, particularly in dining and retail scenarios, with a focus on high-growth companies like Yanjing Beer and Qingdao Beer [7] - The health supplement sector is noted for its potential valuation reconstruction, with a focus on quality stocks [8] Company-Specific Insights - The report on Yingke Recycling indicates strong growth in the decorative building materials business, with a focus on expanding its recycling capabilities and global presence [9] - The analysis of Magmi Te highlights a revenue increase of 16.5% year-on-year in H1 2025, despite a significant drop in net profit due to increased strategic investments [10][11] - The report on Weirgao emphasizes its leadership in the power PCB sector, projecting significant revenue growth driven by AI server demand and production capacity expansion [12] - The analysis of Dacilin shows a revenue increase of 1.33% year-on-year in H1 2025, with a notable profit growth of 21.38% [13] - The report on Dazhu CNC highlights its position as a leader in PCB equipment, benefiting from the demand for high-layer PCB devices driven by AI server needs [14]